9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901

2004 ◽  
Vol 22 (5) ◽  
pp. 398-403 ◽  
Author(s):  
Asim Amin ◽  
Susan Halabi ◽  
Edward P. Gelmann ◽  
Walter Stadler ◽  
Nicholas Vogelzang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Hormone Refractory Prostate Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Hormone Refractory ◽  
Line Chemotherapy

scholarly journals Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients

Cancer ◽  
2007 ◽  
Vol 110 (3) ◽  
pp. 556-563 ◽  
Author(s):  
Jonathan E. Rosenberg ◽  
Vivian K. Weinberg ◽  
W. Kevin Kelly ◽  
Dror Michaelson ◽  
Maha H. Hussain ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Hormone Refractory Prostate Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Hormone Refractory ◽  
Line Chemotherapy

Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?

2005 ◽  
Author(s):  
Karel Odrazka ◽  
Miloslava Vaculikova ◽  
Martin Dolezel ◽  
Jiri Petera ◽  
Petr Moravek ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Hormone Refractory Prostate Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Hormone Refractory ◽  
Line Chemotherapy

scholarly journals First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer

Cancer ◽  
2006 ◽  
Vol 106 (5) ◽  
pp. 1041-1046 ◽  
Author(s):  
Jorg Michels ◽  
Trina Montemurro ◽  
Nevin Murray ◽  
Christian Kollmannsberger ◽  
Kim Nguyen Chi
Keyword(s):  
Prostate Cancer ◽  
Hormone Refractory Prostate Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Hormone Refractory ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document